Aradigm's Linhaliq Suffers 'No' For Reducing Time To Exacerbations At US FDA Panel

Discordant results on Phase III primary endpoint in non-cystic fibrosis bronchiectasis patients troubled advisory committee members, although some suggested they would be more open to approval based upon secondary endpoint data on reduction in exacerbation frequency.

Lungs

For the second time in two months, discordant pivotal trial results led to a negative US FDA advisory committee review of an inhaled ciprofloxacin formulation to treat non-cystic fibrosis bronchiectasis (NCFB).

In the case of Aradigm Corp.'s Linhaliq (ciprofloxacin dispersion for inhalation), however, some of the panelists suggested they could...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from US FDA Performance Tracker

More from Regulatory Trackers